162 related articles for article (PubMed ID: 506543)
21. Field study with a live influenza vaccine (RIT 4050) in children.
Kunz C; Hofmann H
Dev Biol Stand; 1977 Jun 1-3; 39():93-7. PubMed ID: 604139
[TBL] [Abstract][Full Text] [Related]
22. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
23. Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.
Kuwert EK; Höher PG; Werner J; Scheiermann N; Thraenhart O; Müller B; Kleber G
Dev Biol Stand; 1977 Jun 1-3; 39():77-83. PubMed ID: 604137
[TBL] [Abstract][Full Text] [Related]
24. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
[TBL] [Abstract][Full Text] [Related]
25. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy.
Hanania NA; Sockrider M; Castro M; Holbrook JT; Tonascia J; Wise R; Atmar RL;
J Allergy Clin Immunol; 2004 Apr; 113(4):717-24. PubMed ID: 15100679
[TBL] [Abstract][Full Text] [Related]
26. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R
Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505
[TBL] [Abstract][Full Text] [Related]
29. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
[TBL] [Abstract][Full Text] [Related]
30. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine.
Zeman AM; Holmes TH; Stamatis S; Tu W; He XS; Bouvier N; Kemble G; Greenberg HB; Lewis DB; Arvin AM; Dekker CL
Pediatr Infect Dis J; 2007 Feb; 26(2):107-15. PubMed ID: 17259871
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
32. [Capacity of anti-influenza subunit vaccines to elicit the formation of heterologous antibodies].
Profeta ML; Ferrante P
Boll Ist Sieroter Milan; 1981; 60(4):268-77. PubMed ID: 6895694
[TBL] [Abstract][Full Text] [Related]
33. [Studies on sensitization after repeated topic application of live attenuated influenza vaccine (Gripovax) (author's transl)].
Werner J; Kuwert EK
Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):144-54. PubMed ID: 315676
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors.
Bektas O; Karadeniz C; Oguz A; Berberoglu S; Yilmaz N; Citak C
Pediatr Blood Cancer; 2007 Dec; 49(7):914-7. PubMed ID: 17262793
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
[TBL] [Abstract][Full Text] [Related]
36. [Field trial with a new type of influenza subunit vaccine (author's transl)].
Kunz C; Hofmann H
Wien Klin Wochenschr; 1976 Aug; 88(15):504-8. PubMed ID: 997532
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
[TBL] [Abstract][Full Text] [Related]
40. [Vaccination against influenza in children with acute lymphoblastic leukemia].
Jackowska T; Brydak L; Rokicka-Milewska R; Lukowska K; Gosk B; Rudnicka H; Regnery H; Cox N
Pediatr Pol; 1996 Apr; 71(4):301-6. PubMed ID: 8975216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
